Numerous Usability and Functionality Enhancements Increase Phase I Clinic Productivity
Fort Lauderdale, FL, April 21, 2014 –- OmniComm Systems, Inc. (OTCQB: OMCM), a leading global provider of clinical data management solutions for clinical trials, announced the general availability of TrialOne version 4.3. TrialOne is a browser-based, mobile, clinic automation solution designed specifically for early-phase research that facilitates subject recruitment, source data capture, sample tracking, data management and reporting. TrialOne offers time-based data entry and automates many data collection activities via its ability to both print and scan barcodes, as well as to integrate directly with medical monitoring and laboratory equipment. Furthermore, TrialOne’s import and export features provide integration with laboratory information management systems for lab orders and results processing.
After a thorough evaluation process of various commercially available technologies, Surrey CRC selected Promasys technology to manage its clinical research activities. Promasys ranked highest across all categories including ease of use, fast study build, data quality and integrity and volunteer recruitment. Promasys’ versatility through its mobile technology and overall functionality, as well as its lower total cost-of-ownership, was also a significant factor in the decision.
“TrialOne version 4.3 includes numerous productivity and functionality enhancements that drive efficiencies and reduces costs through faster volunteer recruitment, flexible screening questionnaires, direct data capture, work flow automation and modern data processing.”
Enhancements to TrialOne include the following.
Comprehensive integration with bedside patient monitoring, telemetry and clinical devices with enhanced ability to send electrocardiography (ECG) orders to devices such as Mortara Surveyor™ Central System, Seca scales, and Sartorius laboratory balances.
Ability to read ECG tracings in real-time enabling clinic staff to effectively respond to research participants in a timely fashion.
Study teams receive electronic notification alerts of research participant’s adverse experiences allowing them to take appropriate clinical action and medical intervention.
Enhancements in handling treatment blinding allows researchers to effectively track drugs per research participant in adherence to clinical plan and dosages ensuring adherence to clinical protocols where multiple drugs are ordered.
TrialOne now supports open-label (no blinding), single-blinding (participant blinded), double-blinding (floor staff blinded), and triple-blinding (data extract blinded).
“TrialOne continues to set the standard for the automation of early phase clinics,” stated Randy Smith, OmniComm’s CTO and TrialOne Group Executive Sponsor. “The 4.3 release builds on our successful TrialOne suite providing a platform for future planned enhancements”.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm and TrialMaster are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.